Product logins

Find logins to all Clarivate products below.


Chemotherapy | Special Topics | Chemotherapy Forecast – Multi-Indication | G7 | 2020

Chemotherapy has formed the backbone of oncology treatment for decades, and it continues to remain a critical cornerstone of antineoplastic drug therapy. The chemotherapy market is heavily genericized and comprises various drug classes such as taxanes, antimetabolites, and platinum agents. With the advance of targeted therapies and immunotherapies in oncology, the chemotherapy market is also evolving as drug developers aim to incorporate these agents into combination strategies and investigate novel formulations in an effort to improve treatment efficacy and reduce treatment-related side effects. The Chemotherapy Special Topics report provides a comprehensive market forecast of select chemotherapy drugs and drug classes in oncology and analyses the market trends and dynamics across a range of oncology indications.

QUESTIONS ANSWERED

  • What does the current landscape look like for key chemotherapy drugs and drug classes? What are the overarching trends in each indication?
  • How are chemotherapy agents currently positioned in the market? And how will the indication-specific market trends and dynamics evolve for these key drugs and drug classes?
  • What is the commercial potential of current and emerging chemotherapy agents? How will the market evolve over the forecast period?
  • Which novel chemotherapy agents are in clinical development, and what impact can they expect to have in this fast-evolving space?

GOGRAPHIES

United States, EU5, Japan

EPIDEMIOLOGY

Drug-treated patient populations by country and line of therapy for 12 solid tumor indications (bladder cancer, breast cancer, colorectal cancer, gastroesophageal cancer, hepatocellular carcinoma, malignant melanoma, NSCLC, ovarian cancer, pancreatic cancer, prostate cancer, SCCHN and SCLC)) and three hematological malignancies (AML, NHL / CLL, and multiple myeloma).

FORECAST

10-year, annualized, class-level and drug-level sales for chemotherapies through 2028 or 2029, segmented by indication and patient subpopulations.

PRODUCT DESCRIPTION

The Chemotherapy Special Topics report offers a comprehensive market forecast for the chemotherapy landscape in relevant oncology indications through 2028-2029.

Related Market Assessment Reports

Report
Migraine | Special Topics | Spotlight on New Treatments in Migraine (US) | 2021
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
Report
Dry and Wet Age-Related Macular Degeneration | Special Topics | US | 2019
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
Report
Postoperative Pain | Special Topics | US | 2020
Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…
Report
Immune Checkpoint Inhibitors – Special Topics – Special Topics: Trends and Market Dynamics
Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…
Report
Antibody-Drug Conjugates – Special Topics – Special Topics: Trends and Market Dynamics
Antibody-drug conjugates have solidified their position as valuable tools against cancer. The agents combine the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The…